Development of steroid sulfatase inhibitors

Molecular and Cellular Endocrinology

Volumn 340, Issue 2, 2011, Pages 175-185

  Woo, L W Lawrence ^a   Purohit, Atul ^b   Potter, Barry V L ^a  

^a University of Bath   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Dual aromatase and sulfatase inhibitors; Enzyme inhibitors; Hormone dependent breast cancer; Review; Steroid sulfatase; Steroid sulfatase inhibitors

Indexed keywords

17 (N,N DIISOPROPYLCARBAMOYL)ESTRA 1,3,5(10),16 TETRAENE 3 O SULFAMATE; 17ALPHA TERT BUTYLBENZYL 5 ANDROSTEN 17BETA OL; 17BETA (N ALKANOYL)ESTRADIOL 3 O SULFAMATE; 17BETA (N ALKYLCARBAMOYL)ESTRADIOL 3 O SULFAMATE; 2 (1 ADAMANTYL) 4 (THIO)CHROMENONE 6 CARBOXYLIC ACID; 2 (1 ADAMANTYL) 4 CHROMENONE 6 CARBOXYLIC ACID; 2 METHOXY 17ALPHA 4' TERT BUTYLBENZYLESTRADIOL 3 O SULFAMATE; 2 METHOXY 17ALPHA BENZYLESTRADIOL 3 O SULFAMATE; 2 METHOXYESTRONE 3 O SULFAMATE; 4 [N (4 BROMOBENZYL) N (1,2,4 TRIAZOL 4 YL)AMINO]BENZONITRILE; 4 METHYLCOUMARIN 7 O SULFAMATE; ANASTROZOLE; BENZOPHENONE 4,4' BISSULFAMATE; ESTERASE INHIBITOR; ESTRA 1,3,5(10) TRIEN 17 ONE [3,2,E] 1',2',3' OXATHIAZINE 2',2' DIOXIDE; ESTRADIOL 3 O SULFAMATE; ESTRONE 3 O SULFAMATE; ESTRONE SULFATE; IROSUSTAT; LETROZOLE; PGL 2001; SR 16157; STEROID SULFATASE INHIBITOR; STERYL SULFATASE; TETRAHYDRONAPHTHALENE 2 O SULFAMATE; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST TUMOR; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENZYME INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE DRUG DOSE;

DRUG DESIGN; ENZYME INHIBITORS; ESTRONE; HUMANS; STERYL-SULFATASE; SULFONIC ACIDS;

EID: 79960264265     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2010.12.035     Document Type: Review

References (122)

1. Abbate S., Longhi G., Castiglioni E., Lebon F., Wood P.W., Woo L.W.L., Potter B.V.L. Determination of the absolute configuration of aromatase and dual aromatase-sulfatase inhibitors by vibrational and electronic circular dichroism spectra analysis. Chirality 2009, 21:802-808.
2. Adams J.B., Garcia M., Rochefort H. Estrogenic effects of physiological concentrations of 5-androstene-3α,17β-diol and its metabolism in MCF-7 human breast cancer cells. Cancer Res. 1981, 41:4720-4726.
3. Ahmed V., Liu Y., Silvestro C., Taylor S.D. Boronic acids as inhibitors of steroid sulfatase. Bioorg. Med. Chem. 2006, 14:8564-8573.
4. Anderson C.J., Lucas L.J.H., Widlanski T.S. Molecular recognition in biological systems: phosphate esters vs. sulfate esters and the mechanism of action of steroid sulfatases. J. Am. Chem. Soc. 1995, 117:3889-3890.
5. Apsel B., Blair J.A., Gonzalez B., Nazif T.M., Feldman M.E., Aizenstein B., Hoffman R., Williams R.L., Shokat K.M., Knight Z.A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 2008, 4:691-699.
6. Baraldi P.G., Preti D., Fruttarolo F., Tabrizi M.A., Romagnoli R. Hybrid molecules between distamycin A and active moieties of antitumor agents. Bioorg. Med. Chem. 2007, 15:17-35.
7. Birnböck H., von Angerer E. Sulfate derivatives of 2-phenylindoles as novel steroid sulfatase inhibitors. Biochem. Pharmacol. 1990, 39:1709-1713.
8. Boivin R.P., Labrie F., Poirier D. 17α-Alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid sulfatase activity. Steroids 1999, 64:825-833.
9. Boivin R.P., Luu-The V., Lachance R., Labrie F., Poirier D. Structure-activity relationships of 17α-derivatives of estradiol as inhibitors of steroid sulfatase. J. Med. Chem. 2000, 43:4465-4478.
10. Bonneterre J., Buzdar A., Nabholtz J.M.A., Robertson J.F.R., Thurlimann B., von Euler M., Sahmoud T., Webster A., Steinberg M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis. Cancer 2001, 92:2247-2258.
11. Bubert C., Woo L.W.L., Sutcliffe O.B., Mahon M.F., Chander S.K., Purohit A., Reed M.J., Potter B.V.L. Synthesis of aromatase inhibitors and dual aromatase steroid sulfatase inhibitors by linking an arylsulfamate motif to 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile: SAR, crystal structures, in vitro and in vivo activities. ChemMedChem 2008, 3:1708-1730.
12. Chander S.K., Purohit A., Woo L.W.L., Potter B.V.L., Reed M.J. The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates. Biochem. Biophys. Res. Comm. 2004, 322:217-222.
13. Chander S.K., Foster P.A., Leese M.P., Newman S.P., Potter B.V.L., Purohit A., Reed M.J. In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyestradiol. Br. J. Cancer 2007, 96:1368-1376.
14. Chen W.C., Thiboutot D., Zouboulis C.C. Cutaneous androgen metabolism: basic research and clinical perspectives. J. Invest. Dermatol. 2002, 119:992-1007.
15. Chen L., Wilson D., Jayaram H.N., Pankiewicz K.W. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J. Med. Chem. 2007, 50:6685-6691.
16. Chetrite G.S., Cortes-Prieto J., Philippe J.C., Wright F., Pasqualini J.R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 2000, 72:23-27.
17. Chu G.-H., Milano S., Kluth L., Rhodes M., Boni R., Johnson D.A., Li P.-K. Structure-activity relationship studies of the amide functionality in (p-O-sulfamoyl)-N-alkanoyl tyramines as estrone sulfatase inhibitors. Steroids 1997, 62:530-535.
18. Ciobanu L.C., Poirier D. Solid-phase parallel synthesis of 17α-substituted estradiol sulfamate and phenol libraries using the multidetachable sulfamate linker. J. Comb. Chem. 2003, 5:429-440.
19. Ciobanu L.C., Luu-The V., Poirier D. Nonsteroidal compounds designed to mimic potent steroid sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. 2002, 80:339-353.
20. Ciobanu L.C., Boivin R.P., Luu-The V., Poirier D. 3β-Sulfamate derivatives of C19 and C21 steroids bearing a t-butylbenzyl or a benzyl group: synthesis and evaluation as non-estrogenic and nonandrogenic steroid sulfatase inhibitors. J. Enzyme Inhib. Med. Chem. 2003, 18:15-26.
21. Ciobanu L.C., Luu-The V., Martel C., Labrie F., Poirier D. Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase. Cancer Res. 2003, 63:6442-6446.
22. Coombes R., Schmid P., Isambert N., Soulié P., Cardoso F., Besse-Hammer T., Lesimple T., Slosman D., Kornowski A., Fohanno V., Fumoleau P. A phase I dose escalation study of steroid sulfatase inhibitor BN83495/STX64 in postmenopausal women with ER positive breast cancer. Cancer Res. 2009, 69(24 Suppl.):4097. (Abstract).
23. Dauvois S., Labrie F. Androstenedione and androst-5-ene-3α,17β-diol stimulate DMBA-induced mammary tumours-role of aromatase. Breast Cancer Res. Treat. 1989, 13:61-69.
24. Dibbelt L., Li P.-K., Pillai R., Knuppen R. Inhibition of human placental sterylsulfatase by synthetic analogs of estrone sulfate. J. Steroid Biochem. Mol. Biol. 1994, 50:261-266.
25. Duncan L., Purohit A., Howarth N.M., Potter B.V.L., Reed M.J. Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate - a potential therapeutic agent in breast cancer. Cancer Res. 1993, 53:298-303.
26. Elger W., Schwarz S., Hedden A., Reddersen G., Schneider B. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol. 1995, 55:395-403.
27. Elger W., Barth A., Hedden A., Reddersen G., Ritter P., Schneider B., Zuchner J., Krahl E., Muller K., Oettel M., Schwarz S. Estrogen sulfamates: a new approach to oral estrogen therapy. Reprod. Fertil. Dev. 2001, 13:297-305.
28. Espinoza-Fonseca L.M. The benefits of the multi-target approach in drug design and discovery. Bioorg. Med. Chem. 2006, 14:896-897.
29. Evans T.R.J., Rowlands M.G., Jarman M., Coombes R.C. Inhibition of estrone sulfatase enzyme in human placenta and human breast-carcinoma. J. Steroid Biochem. Mol. Biol. 1991, 39:493-499.
30. Fischer D.S., Woo L.W.L., Mahon M.F., Purohit A., Reed M.J., Potter B.V.L. D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. Bioorg. Med. Chem. 2003, 11:1685-1700.
31. Fischer D.S., Chander S.K., Woo L.W.L., Fenton J.C., Purohit A., Reed M.J., Potter B.V.L. Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. J. Steroid Biochem. Mol. Biol. 2003, 84:343-349.
32. Foster P.A., Newman S.P., Chander S.K., Stengel C., Jhalli R., Woo L.W.L., Potter B.V.L., Reed M.J., Purohit A. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin. Cancer Res. 2006, 12:5543-5549.
33. Foster P.A., Chander S.K., Parsons M.F.C., Newman S.P., Woo L.W.L., Potter B.V.L., Reed M.J., Purhit A. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Res. Treat. 2008, 111:129-138.
34. Foulkes R., Shaw S., Suitters A. Immunological consequences of inhibiting dehydroepiandrosterone sulfatase in vivo. Steroid Hormones and the T-cell Cytokine Profile 1997, 135-152. Springer-Verlag, London. G.A.W. Rook, S. Lightman (Eds.).
35. Furet P., Batzl C., Bhatnagar A., Francotte E., Rihs G., Lang M. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J. Med. Chem. 1993, 36:1393-1400.
36. Fusi L., Purohit A., Brosens J., Woo L.W.L., Potter B.V.L., Reed M.J. Inhibition of steroid sulphatase activity in endometriotic implants by 667 Coumate: a potential new therapy. Sci. World J. 2008, 8:1325-1327.
37. Gangjee A., Li W., Yang J., Kisliuk R.L. Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors. J. Med. Chem. 2008, 51:68-76.
38. Gediya L.K., Njar V.C.O. Promise and challenges in drug discovery and development of hybrid anticancer drugs. Expert Opin. Drug Discov. 2009, 4:1099-1111.
39. Gemma S., Campiani G., Butini S., Joshi B.P., Kukreja G., Coccone S.S., Persico M.B.M., Nacci V., Novellino I.F.E., Taramelli D., Basilico N., Parapini S., Yardley V., Croft S., Keller-Maerki S., Rottmann M., Brun R., Coletta M., Marini S., Guiso G., Caccia S., Fattorusso C. Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials. J. Med. Chem. 2009, 52:502-513.
40. Hejaz H.A.M., Purohit A., Mahon M.F., Reed M.J., Potter B.V.L. Synthesis and biological activity of the superestrogen (E)-17-oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: X-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5(10)-estratriene. J. Med. Chem. 1999, 42:3188-3192.
41. Hejaz H.A.M., Woo L.W.L., Purohit A., Reed M.J., Potter B.V.L. Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors of steroid sulphatase. Bioorg. Med. Chem. 2004, 12:2759-2772.
42. Horvath A., Nussbaumer P., Wolff B., Billich A. 2-(1-Adamantyl)-4-(thio)chromenone-6-carboxylic acids: potent reversible inhibitors of human steroid sulfatase. J. Med. Chem. 2004, 47:4268-4276.
43. Howarth N.M., Cooper G., Purohit A., Duncan L., Reed M.J., Potter B.V.L. Phosphonates and thiophosphonates as sulfate surrogates: synthesis of estrone 3-methylthiophosphonate, a potent inhibitor of estrone sulfatase. Bioorg. Med. Chem. Lett. 1993, 3:313-318.
44. Howarth N.M., Purohit A., Reed M.J., Potter B.V.L. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 1994, 37:219-221.
45. Howarth N.M., Purohit A., Reed M.J., Potter B.V.L. Estrone sulfonates as inhibitors of estrone sulfatase. Steroids 1997, 62:346-350.
46. Howarth N.M., Purohit A., Robinson J.J., Vicker N., Reed M.J., Potter B.V.L. Estrone 3-sulfate mimics, inhibitors of estrone sulfatase activity; homology model construction and docking studies. Biochemistry 2002, 41:14801-14814.
47. Ireson C.R., Chander S.K., Purohit A., Parish D.C., Woo L.W.L., Potter B.V.L., Reed M.J. Pharmacokinetics of the non-steroidal steroid sulphatase inhibitor 667COUMATE and its sequestration into red blood cells in rats. Br. J. Cancer 2004, 91:1399-1404.
48. Ishida H., Nakata N., Sato N., Li P.-K., Kuwabara T., Akinaga S. Inhibition of steroid sulfatase activity and cell proliferation in ZR-75-1 and BT-474 human breast cancer cells by KW-2581 in vitro and in vivo. Breast Cancer Res. Treat. 2007, 104:211-219.
49. Ishida H., Nakata T., Suzuki M., Shiotsu Y., Tanaka H., Sato N., Terasaki Y., Takebayashi M., Anazawa H., Murakata C., Li P.-K., Kuwabara T., Akinaga S. A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models. Breast Cancer Res. Treat. 2007, 106:215-227.
50. Ishida H., Sato N., Hosogi J., Tanaka H., Kuwabara T. Inactivation of recombinant human steroid sulfatase by KW-2581. J. Steroid Biochem. Mol. Biol. 2008, 108:17-22.
51. Jackson T., Woo L.W.L., Trusselle M.N., Chander S.K., Purohit A., Reed M.J., Potter B.V.L. Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity. Org. Biomol. Chem. 2007, 5:2940-2952.
52. Jackson T., Woo L.W.L., Trusselle M.N., Chander S.K., Purohit A., Reed M.J., Potter B.V.L. Non-steroidal aromatase inhibitors based on a biphenyl scaffold: synthesis, in vitro SAR, and molecular modelling. ChemMedChem 2008, 3:603-618.
53. James V.H.T., McNeill J.M., Lai L.C., Newton C.J., Ghilchik M.W., Reed M.J. Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 1987, 50:269-279.
54. Jütten P., Schumann W., Härtl A., Heinisch L., Gräfe U., Werner W., Ulbricht H. A novel type of nonsteroidal estrone sulfatase inhibitors. Bioorg. Med. Chem. Lett. 2002, 12:1339-1342.
55. Kolli A., Chu G.H., Rhodes M.E., Inoue K., Selcer K.W., Li P.-K. Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. 1999, 68:31-40.
56. Lapierre J., Ahmed V., Chen Mei-Jin., Ispahany M., Guillemette J.G., Taylor S.D. The difluoromethylene group as a replacement for the labile oxygen in steroid sulfates: a new approach to steroid sulfatase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14:151-155.
57. Lee, W., DeRome, M., DeBear, J., Noell, S., Epstein, D., Mahle, C., DeCarr, L., Woodruff, K., Huang, Z., Dumas, J., 2003. Aryl piperazines: a new class of steroid sulfatase inhibitors for the treatment of hormone-dependent breast cancer. Abstr. Papers J. Am. Chem. Soc. 226:301-Medi Part 2.
58. Leese M.P., Hejaz H.A.M., Mahon M.F., Newman S.P., Purohit A., Reed M.J., Potter B.V.L. A-Ring-substituted estrogen-3-O-sulfamates: Potent multitargeted anticancer agents. J. Med. Chem. 2005, 48:5243-5256.
59. Li P.-K., Pillai R., Young B.L., Bender W.H., Martino D.M., Lin F.T. Synthesis and biochemical studies of estrone sulfatase inhibitors. Steroids 1993, 58:106-111.
60. Li P.-K., Pillai R., Dibbelt L. Estrone sulfate analogs as estrone sulfatase inhibitors. Steroids 1995, 60:299-306.
61. Li P.-K., Rhodes M.E., Jagannathan S., Johnson D.A. Reversal of scopolamine induced amnesia in rats by the steroid sulfatase inhibitor estrone-3-O-sulfamate. Brain Res. Cogn. Brain Res. 1995, 2:251-254.
62. Li P.-K., Rhodes M.E., Burke A.M., Johnson D.A. Memory enhancement mediated by the steroid sulfatase inhibitor (p-O-sulfamoyl)-N-tetradecanoyl tyramine. Life Sci. 1996, 60:45-51.
63. Li P.-K., Milano S., Kluth L., Rhodes M.E. Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. 1996, 59:41-48.
64. Li P.-K., Chu G.H., Guo J.P., Peters A., Selcer K.W. Development of potent non-estrogenic estrone sulfatase inhibitors. Steroids 1998, 63:425-432.
65. Liu Y., Ahmed V., Hill B., Taylor S.D. Synthesis of a non-hydrolyzable estrone sulfate analogue bearing the difluoromethanesulfonamide group and its evaluation as a steroid sulfatase inhibitor. Org. Biomol. Chem. 2005, 3:3329-3335.
66. Lloyd M.D., Pederick R.L., Natesh R., Woo L.W.L., Purohit A., Reed M.J., Acharya K.R., Potter B.V.L. Crystal structure of human carbonic anhydrase II at 1.95Å resolution in complex with 667-coumate, a novel anti-cancer agent. Biochem. J. 2005, 385:715-720.
67. Lloyd M.D., Thiyagarajan N., Ho Y.T., Woo L.W.L., Sutcliffe O.B., Purohit A., Reed M.J., Acharya K.R., Potter B.V.L. First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors. Biochemistry 2005, 44:6858-6866.
68. MacCarthy-Morrogh L., Townsend P.A., Purohit A., Hejaz H.A.M., Potter B.V.L., Reed M.J., Packham G. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res. 2000, 60:5441-5450.
69. Malini B., Purohit A., Ganeshapillai D., Woo L.W.L., Potter B.V.L., Reed M.J. Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates. J. Steroid Biochem. Mol. Biol. 2000, 75:253-258.
70. Marques S.M., Nuti E., Rossello A., Supuran C.T., Tuccinardi T., Martinelli A., Santos M.A. Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates. J. Med. Chem. 2008, 51:7968-7979.
71. Meunier B. Hybrid molecules with a dual mode of action: dream or realityŽ. Acc. Chem. Res. 2008, 41:69-77.
72. Milla-Santos A., Milla L., Portella J., Rallo L., Pons M., Rodes E., Casanovas J., Puig-Gali M. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer. A prospective, randomized, phase III study. Am. J. Clin. Oncol. 2003, 26:317-322.
73. Morphy R., Rankovic Z. Designed multiple ligands. an emerging drug discovery paradigm. J. Med. Chem. 2005, 48:6523-6543.
74. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Janicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Lassus M., Verbeek J.A., Staffler B., Chaudri-Ross H.A., Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the international letrozole breast cancer group. J. Clin. Oncol. 2001, 19:2596-2606.
75. Mouridsen H., Gershanovick M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Jaenicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Chaudri-Ross H., Lang R., Wyld P., Bhatnagar A. Phase III study of letrozole versus tamoxifen as firstline therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group. J. Clin. Oncol. 2003, 21:2101-2109.
76. Nabholtz J.M. Advanced breast cancer updates on anastrozole versus tamoxifen. J. Steroid Biochem. Mol. Biol. 2003, 86:321-325.
77. Nabholtz J.M., Bonneterre J., Buzdar A., Robertson J.F.R., Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur. J. Cancer 2003, 39:1684-1689.
78. Naitoh K., Honjo H., Yamamoto T., Urabe M., Ogino Y., Yasumura T., Nambara T. Oestrone sulphate and sulphatase activity in human breast cancer and endometrial cancer. J. Steroid Biochem. 1989, 33:1049-1054.
79. Newman S.P., Leese M.P., Purohit A., James D.R., Rennie C.E., Potter B.V.L., Reed M.J. Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int. J. Cancer 2004, 109:533-540.
80. Nussbaumer P., Lehr P., Billich A. 2-Substituted 4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase. J. Med. Chem. 2002, 45:4310-4320.
81. Nussbaumer P., Bilban M., Billich A. 4,4′-Benzophenone-O,O′-disulfamate: a potent inhibitor of human steroid sulfatase. Bioorg. Med. Chem. Lett. 2002, 12:2093-2095.
82. Nussbaumer P., Winiski A.P., Billich A. Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates, potent inhibitors of human steroid sulfatase. J. Med. Chem. 2003, 46:5091-5094.
83. Nussbaumer P., Geyl D., Horvath A., Lehr P., Wolff B., Billich A. Nortropinyl-arylsulfonylureas as novel, reversible inhibitors of human steroid sulfatase. Bioorg. Med. Chem. Lett. 2003, 13:3673-3677.
84. Paridaens R., Dirix L., Lohrisch C., Beex L., Nooij M., Cameron D., Biganzoli L., Cufer T., Duchatea L., Hamilton A., Lobelle J.P., Piccart M. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann. Oncol. 2003, 14:1391-1398.
85. Peters R.H., Chao W.-R., Sato B., Shigeno K., Zaveri N.T., Tanabe M. Steroidal oxathiazine inhibitors of estrone sulfatase. Steroids 2003, 68:97-110.
86. Poirier D., Boivin R.P. 17α-alkyl- or 17-α-substituted benzyl-17β-estradiols: a new family of estrone sulfatase inhibitors. Bioorg. Med. Chem. Lett. 1998, 8:1891-1896.
87. Poirier D., Ciobanu L.C., Bérubé M. A multidetachable sulfamate linker successfully used in a solid-phase strategy to generate libraries of sulfamate and phenol derivatives. Bioorg. Med. Chem. Lett. 2002, 12:2833-2838.
88. Purohit A., Howarth N.M., Potter B.V.L., Reed M.J. Inhibition of steroid sulphatase activity by steroidal methylthiophosphonates: potential therapeutic agents in breast cancer. J. Steroid Biochem. Mol. Biol. 1994, 48:523-527.
89. Purohit A., Williams G.J., Roberts C.J., Potter B.V.L., Reed M.J. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int. J. Cancer 1995, 63:106-111.
90. Purohit A., Vernon K.A., Hummelinck A.E.W., Woo L.W.L., Hejaz H.A.M., Potter B.V.L., Reed M.J. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J. Steroid Biochem. Mol. Biol. 1998, 64:269-275.
91. Purohit A., Hejaz H.A.M., Woo L.W.L., van Strien A.E., Potter B.V.L., Reed M.J. Recent advances in the development of steroid sulphatase inhibitors. J. Steroid Biochem. Mol. Biol. 1999, 69:227-238.
92. Purohit A., Woo L.W.L., Potter B.V.L., Reed M.J. In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea induced mammary tumors by 667COUMATE. Cancer Res. 2000, 60:3394-3396.
93. Purohit A., Woo L.W.L., Barrow D., Hejaz H., Nicholson R.I., Potter B.V.L., Reed M.J. Non-steroidal and steroidal sulfamates: new drugs for cancer therapy. Mol. Cell. Endocrinol. 2001, 171:129-135.
94. Purohit A., Fusi L., Brosens J., Parish D., Fernandes M.S., Woo L.W.L., Potter B.V.L., Reed M.J. Inhibition of steroid sulphatase activity in endometriotic implants by 667COUMATE: a potential new therapy. Human Reprod. 2008, 23:290-297.
95. Purohit A., Chander S.K., Woo L.W.L., Parsons M.F.C., Jhalli R., Potter B.V.L., Reed M.J. Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy. Anticancer Res. 2008, 28:1517-1523.
96. Raobaikady B., Purohit A., Chander S.K., Woo L.W.L., Leese M.P., Potter B.V.L., Reed M.J. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J. Steroid Biochem. Mol. Biol. 2003, 84:351-358.
97. Reed M.J., Purohit A., Woo L.W.L., Potter B.V.L. The development of steroid sulphatase inhibitors. Endocr. Rel. Cancer 1996, 3:9-23.
98. Reed J.E., Woo L.W.L., Robinson J.J., Leblond B., Leese M., Purohit A., Reed M.J., Potter B.V.L. 2-Difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. Comm. 2004, 317:169-175.
99. Reed M.J., Purohit A., Woo L.W.L., Potter B.V.L. Steroid sulphatase inhibitors as a target for the topical treatment of skin disorders. Drugs Future 2008, 33:597-606.
100. Sambucetti L., Green C., Rausch L., Chao W., Lee Valley S., Zaveri N., Mirsalis J. SR16157 is a potent dual-acting inhibitor of estrogen biosynthesis and estrogen receptor. Cancer Res. 2009, 69:5124. (Meeting Abstract Supplement).
101. Santner S.J., Feil P.D., Santen R.J. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance vs. the aromatase pathway. J. Clin. Endocrinol. Metab. 1984, 59:29-33.
102. Selcer K.W., Hegde P.V., Li P.-K. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines. Cancer Res. 1997, 57:702-707.
103. Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. N. Eng. J. Med. 2003, 348:2431-2442.
104. Stanway S.J., Purohit A., Woo L.W.L., Sufi S., Vigushin D., Ward R., Wilson R.H., Stanczyk F.Z., Dobbs N., Kulinskaya E., Elliott M., Potter B.V.L., Reed M.J., Coombes R.C. Phase I study of STX64 (667Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 2006, 12:1585-1592.
105. Stanway S.J., Delavault P., Purohit A., Woo L.W.L., Thurieau C., Potter B.V.L., Reed M.J. Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist 2007, 12:370-374.
106. Suzuki T., Nakata T., Miki Y., Kaneko C., Moriya T., Ishida T., Akinaga S., Hirakawa H., Kimura M., Sasano H. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. 2003, 63:2762-2770.
107. ®) in advanced solid malignancies. Clin. Cancer Res. 2009, 15:1460-1465.
108. Utsumi T., Yoshimura N., Takeuchi S., Ando J., Maruta M., Maeda K., Harada N. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. 1999, 59:377-381.
109. Wei D., Jiang X., Zhou L., Chen J., Chen Z., He C., Yang K., Liu Y., Pei J., Lai L. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J. Med. Chem. 2008, 51:7882-7888.
110. Wong C.K., Keung W.M. Daidzein sulfoconjugates are potent inhibitors of sterol sulfatase (EC 3.1.6.2). Biochem. Biophys. Res. Commun. 1997, 233:579-583.
111. Woo L.W.L., Lightowler M., Purohit A., Reed M.J., Potter B.V.L. Heteroatom-substituted analogues of the active site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. J. Steroid Biochem. Mol. Biol. 1996, 57:79-88.
112. Woo L.W.L., Purohit A., Reed M.J., Potter B.V.L. Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates. J. Med. Chem. 1996, 39:1349-1351.
113. Woo L.W.L., Purohit A., Reed M.J., Potter B.V.L. Oestrone 3-O-(N-acetyl)sulphamate, a potential molecular probe of the active site of oestrone sulphatase. Bioorg. Med. Chem. Lett. 1997, 7:3075-3080.
114. Woo L.W.L., Howarth N.M., Purohit A., Hejaz H.A.M., Reed M.J., Potter B.V.L. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J. Med. Chem. 1998, 41:1068-1083.
115. Woo L.W.L., Purohit A., Malini B., Reed M.J., Potter B.V.L. Potent active site-directed inhibition of steroid sulfatase by tricyclic coumarin-based sulphamates. Chem. Biol. 2000, 7:773-791.
116. Woo L.W.L., Sutcliffe O.B., Bubert C., Grasso A., Chander S.K., Purohit A., Reed M.J., Potter B.V.L. First dual aromatase-steroid sulfatase inhibitors. J. Med. Chem. 2003, 46:3193-3196.
117. Woo L.W.L., Bubert C., Sutcliffe O.B., Smith A., Chander S.K., Mahon M.F., Purohit A., Reed M.J., Potter B.V.L. Dual aromatase-steroid sulfatase inhibitors. J. Med. Chem. 2007, 50:3540-3560.
118. Woo L.W.L., Fischer D.S., Sharland C.M., Trusselle M., Foster P.A., Chander S.K., Di Fiore A., Supuran C.T., De Simone G., Purohit A., Reed M.J., Potter B.V.L. Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography. Mol. Cancer Ther. 2008, 7:2435-2444.
119. Woo L.W.L., Jackson T., Putey A., Cozier G., Leonard P., Acharya K.R., Chander S.K., Purohit A., Reed M.J., Potter B.V.L. Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J. Med. Chem. 2010, 53:2155-2170.
120. Wood P.M., Woo L.W.L., Humphreys A., Chander S.K., Purohit A., Reed M.J., Potter B.V.L. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. J. Steroid Biochem. Mol. Biol. 2005, 94:123-130.
121. Wood P.M., Woo L.W.L., Labrosse J.R., Trusselle M.N., Abbate S., Longhi G., Castiglioni E., Lebon F., Purohit A., Reed M.J., Potter B.V.L. Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity. J. Med. Chem. 2008, 51:4226-4238.
122. Wood P.M., Woo L.W.L., Labrosse J.-R., Thomas M.P., Mahon M.F., Chander S.K., Purohit A., Potter B.V.L. Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-bromo-4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl} phenylsulfamate: synthesis, SAR, crystal structure, and in vitro and in vivo activities. Chem. Med. Chem. 2010, 5:1577-1593.